Mahmood Shams

Dr. Mahmood Shams

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2019 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
STShadi Tabibian
Shadi Tabibian
YSYavar Shiravand
Yavar Shiravand
MSMahmood Shams
Mahmood Shams
MSMajid Safa
Majid Safa
MGMohammad Saeed Gholami
Mohammad Saeed Gholami
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
Coagulation factor (F) V is a glycoprotein that plays an essential role in the formation of the prothrombinase complex, which is critical for progressing clot formation. FV deficiency is a rare bleeding disorder with an estimated incidence of one per 1 million in the general population. The disorder is manifested with a wide array of clinical bleeding events. The most common bleeding features of FV deficiency are mucosal bleedings. Life-threatening manifestations are rarely seen in this disorder. FV deficiency is diagnosed using routine coagulation tests and FV activity assay. A wide spectrum of mutations including missense, nonsense, and frameshift is observed throughout the F5 gene. Although fresh frozen plasma is the dominant therapeutic choice, a newly introduced plasma-derived FV concentrate was found effective in in vitro correction of prothrombin time, activated partial thromboplastin time, and thrombin generation parameters in severe FV deficiency and should provide more targeted treatment for patients with FV deficiency in the future.

19 April 2023 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
MSMohammad Sayyadi
Mohammad Sayyadi
SHSaeed Hassani
Saeed Hassani
MSMahmood Shams
Mahmood Shams
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
The coagulation, fibrinolytic, anticoagulation, and complement systems are in delicate balance with the vessel wall endothelium ensuring appropriate hemostasis. Coagulopathy in coronavirus disease 2019 (COVID-19) is not a simple disorder of one hemostatic component but a complicated process affecting most of the hemostasis system. COVID-19 disturbs the balance between the procoagulant systems and the regulatory mechanisms. Here, we investigate the effect of COVID-19 on key hemostatic components, including platelets, endothelial cells, coagulation factors, fibrinolytic system, anticoagulant protein system, and complement system, to improve our understanding of the pathophysiological processes underlying COVID-19 coagulopathy based on evidence.

26 June 2016 in Laboratory Medicine
Verified
Journal Article
Open access
PDF file
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
STShadi Tabibian
Shadi Tabibian
MSMahmood Shams
Mahmood Shams
BTBehnaz Tavasoli
Behnaz Tavasoli
MGMaryam Gheidishahran
Maryam Gheidishahran
MSMorteza of Shamsizadeh
Morteza of Shamsizadeh
Factor XIII deficiency (FXIIID) is an extremely rare bleeding disorder with an approximately 12-times higher than the rest of the world. The International Society for Thrombosis and Hemostasis (ISTH) suggested a standard algorithm for precise diagnosis and classification of FXIIID. However, due to lack of investment in proper equipment and procedures in Iran, almost no part of this algorithm can be used to diagnose Iranian patients. Thus, this study proposes a guideline for accurate molecular and laboratory diagnosis of FXIIID based on the available tools. Because this study suggests a simple and reliable algorithm for early diagnosis, it can therefore, reduce the rates of morbidity and mortality of FXIIID patients with this condition. * Abbreviations : FXIII : Factor XIII FXIIID : Factor XIII deficiency RBD : rare bleeding disorder RPL : recurrent pregnancy loss CNS : central nervous system FFP : fresh frozen plasma rFXIII : recombinant FXIII BT : bleeding time PT : prothrombin time APTT : activated partial thromboplastin time CaCl2 : calcium chloride MCA : monochloroacetic ISTH : International Society for Thrombosis and Hemostasis IgG : immunoglobulin G ELISA : enzyme-linked immunosorbent assay SDS : sodium dodecyl sulfate PAGE : polyacrylamide gel electrophoresis PND : prenatal diagnosis PPP : platelet-poor plasma FXIIIa : activated FXIII NADPH : nicotinamide adenine dinucleotide phosphate hydrogen NADP : nicotinamide adenine dinucleotide phosphate

24 February 2018 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
STShadi Tabibian
Shadi Tabibian
MSMahmood Shams
Mahmood Shams
MNM. Naderi
M. Naderi
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh

10 January 2019 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
STShadi Tabibian
Shadi Tabibian
MSMahmood Shams
Mahmood Shams
GMGolbahar Majid
Golbahar Majid
MNMajid Naderi
Majid Naderi
MSMajid Safa
Majid Safa
Congenital factor XIII (FXIII) deficiency is an extremely rare hemorrhagic disorder characterized by a deficiency of FXIII and associated with a high rate of morbidity and mortality. The disorder is more frequent in Iran, especially in Khash, a city in the southeast of the country. As identified in the current report, the prevalence of FXIII deficiency in this city is 1 homozygote per approximately 500 population (which is ∼4,000 times higher than the worldwide prevalence) with 3.5% heterozygotes. The disorder is accompanied by a high rate of mortality in rural areas of Khash, given an averaged observed rate of approximately three deaths per each family with FXIII deficiency, mostly due to late-diagnosis and/or misdiagnosis, and fetal consequences of both umbilical cord and central nervous system bleeding. Almost all patients with FXIII deficiency in the southeast Iran have a unique mutation in F13A gene (Trp187Arg), which leads to a severe FXIII deficiency. This mutation is used for pre-marriage and prenatal diagnosis, as well as for carrier detection and diagnostic confirmation. Fibrogammin P has been used worldwide for about one decade, along with different therapeutic regimens for prophylaxis treatment, major and minor surgeries, and successful delivery. Due to the rapid increase in the number of patients identified to have congenital FXIII deficiency, and the high rate of related morbidity and mortality, a comprehensive regional preventive program is necessary to prevent further expansion of this condition and decrease the burden on the health care system. The area of Khash city provides novel insights into severe FXIII deficiency due to its high prevalence in this region. This report also provides a review of FXIII deficiency, its diagnosis, prevalence, molecular basis, clinical manifestations, management, and treatment, with a particular focus on Iran, representing a hotspot for this disorder.

1 January 2019 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
MSMahmood Shams
Mahmood Shams
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
NSNader Safarian
Nader Safarian
AEAmir Hossein Emami
Amir Hossein Emami
FZFarhad Zaker
Farhad Zaker
MRMohammad Reza Rezvani
Mohammad Reza Rezvani
Congenital factor VII (FVII) deficiency is a rare bleeding disorder with an estimated prevalence of 1 per 500 000 in the general population. On-demand replacement therapy is the main therapeutic choice in patients with congenital FVII deficiency. Inhibitor formation against exogenous FVII is very rare and can cause challenges in the management of the disorder. The present study was conducted to assess the prevalence of FVII inhibitor in 50 patients with congenital FVII deficiency under on-demand or prophylaxis treatment by recombinant activated FVII. All patients with confirmed congenital FVII deficiency were assessed for inhibitor development in regular intervals. Inhibitor titer was determined by a modified Nijmegen–Bethesda assay. The study results were analyzed by SPSS software. Among all cases, two patients (4%) developed an FVII inhibitor. Case 1 was a 14-year-old boy with severe FVII deficiency (FVII activity <1%) with regular prophylaxis. The patient was a high-responder with high-titer FVII inhibitor (170 Bethesda Unit). This patient, who had a history of intracranial hemorrhage, had undergone brain surgery three times. The second patient was a 70-years old man with on-demand therapy that also developed a high-titer inhibitor (10 Bethesda Unit). This patient had experienced easy bruising and endured a few surgeries for his brain tumor and, finally, succumbed to the disease. Although the inhibitor formation is a rare phenomenon, it may result in a significant challenge to manage the affected patients.